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INTRODUCTION
It has been reported that a high dose chemotherapy with
autologous stem cell transplantation (ASCT) enhances pa-
tient’ s survival rate and suppresses the recurrence rate in
chemo-sensitive primary tumors such as non-Hodgkin’ s
lymphoma (1). However, the treatment also produces delayed
toxicities including treatment-related myelodysplastic syn-
drome (t-MDS) and acute myelogenous leukemia (t-AML).
Among the chemotherapeutic agents, etoposide, a topoiso-
merase II inhibitor is well-known to cause t-AML with a chrac-
teristic chromosomal abnormality of 11q23 rearrangement
(2). We report here a case of a 28-yr-old Korean woman with
t-MDS and t-AML with progressively evolving cytogenetic
abnomalities including 11q23 rearrangement after BCNU/
etoposide/Ara-C/cytoxan high-dose chemotherapy and ASCT
for non-Hodgkin’ s lymphoma.
CASE REPORT
A 28-yr-old, four months pregnant woman was admitted
with complaints of an icteric skin change and right upper
quadrant abdominal mass. Her blood pressure was 120/80
mmHg, pulse rate 100/min, respiration rate 18/min, and
body temperature 36.0℃. Her skin and sclera were icteric.
Respiratory and heart sounds were normal. A huge non-ten-
der, 10×10 cm sized hard mass was palpable on the right
upper quadrant of the abdomen. 
The initial laboratory findings were as follows: white blood
cell count 7,800/ L (seg 91%, lymphocyte 6%, and mono-
cyte 3%), hemoglobin 8.3 g/dL, hematocrit 24.5%, and
platelet count 296,000/ L on complete blood cell count
(CBC), blood urea nitrogen 5 mg/dL, creatinine 0.5 mg/dL,
protein 6.4 g/dL, albumin 4.0 g/dL, aspartate aminotrans-
ferase 38 IU/L, alanine aminotransferase 37 IU/L, total biliru-
bin 11.1 mg/dL, and direct bilirubin 5.6 mg/dL on blood
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A Case of Treatment-Related Myelodysplastic syndrome and Acute
Myelogenous Leukemia Following High-Dose Chemotherapy with
Autologous Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Treatment-related myelodysplastic syndrome (t-MDS) and acute myelogenous
leukemia (t-AML) are now well established as complications of cytotoxic che-
motherapy. We experienced a 28-yr-old female patient who developed t-MDS/t-
AML with characteristic chromosomal abnormalities including 11q23 chromoso-
mal rearrangement following high-dose chemotherapy with autologous stem cell
transplantation (ASCT) for non-Hodgkin’ s lymphoma. The patient was admitted
with bulky abdominal masses of B cell lineage non-Hodgkin’ s lymphoma. After 2
cycles of systemic chemotherapy of the Vanderbilt regimen, the patient under-
went ASCT with high dose chemotherapy of the BEAC regimen. She also received
radiation of 48 Gy for the residual periportal lymphadenopathy. The initial cyto-
genetic analysis of the infused mononuclear cells revealed a normal karyotype.
Twenty two months after the ASCT, pancytopenia was noted and her bone mar-
row aspirate showed dysplastic hemopoiesis with myeloblasts up to 12% of non-
erythroid nucleated cells. The patient was diagnosed as t-MDS (refractory ane-
mia with an excess of blasts). Cytogenetic analysis showed complex chromoso-
mal abnormalities including 11q23 rearrangement, which is frequently found in
topoisomerase II inhibitor-related hematologic malignancies. Four months later,
it was noted that the t-MDS had evolved into an overt t-AML. Cytogenetic analysis
showed an evolving pattern with more complex abnormalities. The patient was
treated with combination che-motherapy, but her leukemic cells were resistant to
the therapy.
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Fig. 1. (A) A bulky mass is noted by abdominopelvic CT scan at the initial diagnosis; (B) The mass size decreases after 2 cycles of
chemotherapy of the Vanderbilt regimen.
chemistry. Bilirubin was +++, urobilinogen +, WBC ±on
routine urinalysis. No abnormality was found on chest radio-
graphy and computed axial tomography (CT) scan of the
chest. A bulky mass compressing the common bile duct (Fig.
1A) with an involvement of porta caval space and another
mass near the left common and internal iliac arteries were
detected on CT scan of the abdomen and pelvis. The mass
proved to be a malignant lymphoma of B cell lineage by posi-
tive immunohistochemical staining against pan B (L-26) (Fig.
2) with percutaneous needle biopsy. There was no evidence
of bone marrow involvement by lymphoma and the result
of chromosomal study was normal. 
The patient was diagnosed as malignant B cell lymphoma,
and treated with percutaneous transhepatic biliary drainage
and artificial termination. Then she was given 2 cycles of
chemotherapy of the Vanderbilt regimen (cycle 1; cytoxan
1,500 mg/m2 day 1, 2, etoposide 400 mg/m2 day 1-3, vin-
cristine 1.4 mg/m2 day 8, 22, bleomycin 10 U/m2 day 8, 22,
methotrexate 200 mg/m2 day 15, leucovorin 15 mg/m2 q 6 hr
for 6 doses 24 hr after methotrexate, prednisolone 60 mg/m2
day 1-7, cycle 2; cytoxan 1,500 mg/m2 day 29, etoposide 100
mg/m2day 29-31, doxorubicin 45 mg/m2day 1, 2, Bleomycin
10 U/m2 day 36, 50, methotrexate 200 mg/m2 day 43, leu-
covorin 15 mg/m2 q 6 hr for 6 doses 24 hr after methotrex-
ate, prednisolone 60 mg/m2 day 29-35) chemotherapy (3).
A partial remission was observed on a follow-up CT scan
(Fig. 1B). Cytoxan (4 g/m2) and granulocyte-colony stimu-
lating factor (G-CSF, 10  g/kg) were adminstered for stem
cell mobilization, and the BEAC regimen (BCNU 300 mg/
m2, etoposide 800 mg/m2, cytarabine 800 mg/m2, and cytox-
an 140 mg/kg) was employed for the conditioning of ASCT
(4). 
On the 27th day after ASCT, her CBC (WBC 3,200/ L,
Hb 10.9 g/dL, and platelet 119,000/ L) suggested a suc-
cessful engraftment. Follow-up CT scan revealed much more
decreased abdominal mass. She received radiotherapy of 48
Gy on periportal area for the residual mass. Afterward, she
was followed-up on an outpatient basis in a near complete
Fig. 2. Light microscopic finding (×200) of B cell lineage non-
Hodgkin’ s lymphoma showing positive immunohistochemical
staining against a pan B antigen (L-26). Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia 557
remission state.
Twenty two months after the ASCT, her CBC showed a
progressive pancytopenia. Her bone marrow examination
revealed slightly hypogranular granulocytes with an increase
of myeloblasts (12% of nonerythroid nucleated cells, Fig.
3A). She was diagnosed with refractory anemia with an excess
of blasts according to the FAB classification. Chromosomal
study showed complex abnormalities including trisomy 6
and t(11;11)(q23;q25) (Fig. 4A). Because an HLA-compati-
ble related donor was not available, she had to wait for an
HLA-matched unrelated donor from the bone marrow reg-
istry receiving a supportive care. The chromosomal study of
the patient’ s frozen mononucler cells that had been stored
after mobilization did not show any cytogenetic abnormali-
ties.
Four months after the diagnosis of t-MDS, she was read-
mitted due to cough and purulent sputum. A consolidated
lesion was found in the right lower lobe of her lung by chest
radiography. Peripheral blood smear revealed blasts up to 27%
and bone marrow aspiration and biopsy showed large clusters
of myeloblasts (50% of nonerythroid nucleated cells) (Fig.
3B). Chromosomal study showed more complex abnormali-
ties than before (Fig. 4B).
After alleviation of pneumonic consolidation, the patient
was treated with cytarabine and idarubicine chemotherapy
for t-AML. However her bone marrow on day 14 harbored
A B
Fig. 3. Light microscopic findings of bone marrow. (A) t-MDS with hypogranular granulocytes and increased myeloblasts (12% of
nonerythroid nucleated cells, ×1,000). (B) t-AML with a large cluster of leukemic blasts (50% of nonerythroid nucleated cells, ×400).
A B
Fig. 4. Cytogenetic analysis of bone marrow. (A) Complex chromosomal abnormalities including +6, del(9)(q12q32), and
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persistent leukemic cells. Pneumonic consolidation reap-
peared along with severe neutropenia. Despite aggressive
treatment with broad-spectrum antibiotics, amphotericin
B, and G-CSF, the patient eventually succumbed to her dis-
ease.
DISCUSSION
The employment of high-dose chemotherapy has improved
the survival of patients with malignancies such as non-Hodg-
kin’ s lymphoma (1). However its long-term effects are of
increasing concern. One of the most serious adverse effects
is the development of secondary malignancies including
treatment-related leukemia (5).
MDS and acute leukemia are clonal neoplastic hemato-
logic disorders from various causes such as familial factor,
ionizing radiation, benzene, and chemotherapeutic agents.
It is well known that chemotherapy or radiotherapy of pri-
mary cancer can induce t-MDS and t-AML especially in pa-
tients with Hodgkin’ s and non-Hodgkin’ s lymphomas who
received high-dose chemotherapy with or without total body
irradiation for ASCT (24). These patients represent the high-
est risk group to develop t-MDS and/or t-AML between 2-
8 yr following therapy, and most have chromosomal abnor-
malities that were not present at the time of diagnosis of the
primary cancer (6).
Recently, it has become evident that there are at least two
different forms of chemotherapy-related leukemia: alkylat-
ing agent-related and topoisomerase II inhibitor-related
leukemias. Alkylating agents such as cyclophosphamide,
melphalan, busulfan, semustine, and carmustine have been
implicated in t-MDS and t-AML. These agents form covalent
bonds between the carbon of an alkyl moiety and nucleophilic
DNA bases. These induce both intra- and interstrand DNA
cross-linkings and breaks and the DNA cross-linking causes
a DNA misleading. Although the leukemogenicity of the
alkylating agents is not fully known, they may induce leuke-
mia through such mechanisms as point mutations, deletions,
and inappropriate recombinations, because of the enhanced
and aberrant DNA repair (7, 8). There are evidences that
the leukemogenic risk is dose dependent (9, 10) and most t-
AML present initially as myelodysplasia and develop within
1 yr from the diagnosis of MDS (11). Cytogenetic studies
have shown unbalanced chromosomal aberrations, most
commonly the loss of whole chromosomes 5 or 7, or various
parts of the long arms of these chromosomes (11, 12). Mor-
phologically, the French-American-British (FAB) subtypes
M1, M2, M6, M7 and even undetermined phenotypes have
been reported (13).  
It is thought that topoisomerase II inhibitors such as etopo-
side (VP-16) and teniposide induce secondary leukemias by
inhibition of the topoisomerase II, which regulates the super-
helical rearrangement of the DNA. The enzyme cleaves a
single strand of the DNA duplexes at a specific sites by a
covalent binding between its tyrosine residue and 5′ -phos-
phate residue of the DNA, and produces a transient double
strand break, which enables the knotted or interlinked DNA
to pass (14-16). Thus topoisomerase II inhibitor produces
secondary DNA damages such as a complex conversion. In
the process of repair, an illegitimate and non-homologous
recombination can occur and this may be responsible for
leukemogenic potential. Topoisomerase II inhibitor-related
leukemia has a relatively short incubation period, median 2
to 3 yr following treatment without a prodromal myelodys-
plastic phase compared to alkylating agent-related leukemia
(13). The chromosomal study may show the characteristic
balanced translocations involving chromosome band 11q23
or less often, 21q22 (17-20). Common partner chromosomes
for the 11q23 translocations are the chromosomes 1, 2, 4, 6,
9, 10, 16, 17, 19, 22, and X (13). These chromosomal aber-
rations are more frequently associated with the development
of AML M4 or M5 according to the FAB classification (16,
19). The mixed lineage leukemia (MLL) gene is located at
chromosomal band 11q23 and is frequently involved in t-
AML following topoisomerase II inhibitor treatment (21).
Recently, Krishnan et al. reported 22 patients with morpho-
logic evidence of t-MDS and t-AML among 612 patients who
had been treated with high-dose chemotherapy with ASCT
for Hodgkin’ s disease and non-Hodgkin’ s lymphoma (22).
A multivariate analysis of the entire cohort revealed that the
stem cell priming with etoposide (relative risk 7.7, p value=
0.002) was independently associated with an increased risk
of developing a secondary leukemia with the 11q23/21q22
abnormalities. 
A cumulative dose of etoposide higher than 2-3 g/m2 is
known to be associated with the development of t-AML,
although this association has not been found in all studies
(23). In this case, a total of 2.3 g/m2 cumulative dose of etopo-
side was given as well as alkylating agents and irradiation.
The patient was diagnosed with t-MDS 22 months after
ASCT, which progressed to t-AML after 4 months. The cyto-
genetic studies revealved a normal karyotype before ASCT,
the 11q23 rearrangement within chrmosome 11 at the diag-
nosis of t-MDS, and more complex chromosomal abnormal-
ities at t-AML.
In conclusion, our patient suffered from t-MDS/t-AML
following an aggressive treatment for non-Hodgkin’ s lym-
phoma. Her characteristic 11q23 rearrangement might be
attributed to the use of a high cumulative dose of topoiso-
merase II inhibitor, etoposide. 
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